{"id":12826,"date":"2021-11-10T13:11:00","date_gmt":"2021-11-10T07:41:00","guid":{"rendered":"https:\/\/www.rootsanalysis.com\/blog\/?p=12826"},"modified":"2025-07-31T17:52:27","modified_gmt":"2025-07-31T12:22:27","slug":"adc-therapeutics-alternative-to-traditional-anticancer-therapies","status":"publish","type":"post","link":"https:\/\/www.rootsanalysis.com\/blog\/adc-therapeutics-alternative-to-traditional-anticancer-therapies\/","title":{"rendered":"ADC Therapeutics \u2013 Alternative to Traditional Anticancer Therapies"},"content":{"rendered":"\n

Antibody-drug conjugates (ADCs) are an upcoming class of targeted therapeutic agents that have captured the attention of both large and small pharmaceutical companies, and academic \/ research institutions from all across the world. Fundamentally, these complex biotherapeutic entities demonstrate the combination of target specificity of an antibody and therapeutic features of a chemotherapy \/ cytotoxic drug. Such conjugates are believed to be more efficient and effective in specifically identifying and eliminating cells\/pathogens that are associated with the disease(s). ADC therapeutics are presently an established concept with eleven approved products. Despite the challenges associated with ADC development and ADC contract manufacturing<\/a>, they have still considered a revolutionary technology over their components, such as the naked antibodies and drugs (cytotoxins).<\/p>\n\n\n\n

Increased Partnership Activity in ADC Therapeutics Domain<\/h2>\n\n\n\n

Partnership activity has increased steadily over the years in ADC Therapeutics, involving the participation of both indigenous and international stakeholders.<\/p>\n\n\n\n

\"ADC<\/figure>\n\n\n\n

Combination therapy has gained significant popularity over the stand-alone therapies<\/strong><\/strong><\/h3>\n\n\n\n

Several ADC therapeutics developers have recently evaluated their pipeline candidates as combination products<\/a> with other therapeutic modalities for the treatment of various oncological disorders.<\/p>\n\n\n\n

\"ADC<\/figure>\n\n\n\n

Several Clinical Trials Focused on the Evaluation of ADC Therapeutics have been Registered Over the Past Few Years<\/strong><\/h4>\n\n\n\n

Multiple clinical studies, evaluating various types of ADC Therapeutics, and involving nearly 24,000 patients across different centers \/ hospitals, have been initiated worldwide.<\/p>\n\n\n

\n
\"ADC<\/figure>\n<\/div>\n\n\n

Conclusion<\/strong><\/p>\n\n\n\n

Given their clinically proven benefits, ADC Therapeutics are being widely explored for a wide array of indications, which are not only limited to cancer. In fact, multiple clinical trials are currently evaluating the potential of ADC therapies<\/a> for the treatment of autoimmune disorders, such as rheumatoid arthritis. With 11 approved ADCs are many others in late stages of clinical development, the antibody drug conjugate market<\/a> is poised to witness significant growth in the foreseen future.<\/p>\n\n\n\n

For more details, you can also download the\u00a0SAMPLE REPORT<\/a>\u00a0on ADC therapies by Roots Analysis.<\/p>\n\n\n\n

Our Social Media Platform<\/strong><\/p>\n\n\n\n